{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:14:33Z","timestamp":1793682873104,"version":"4.5.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["468853597"],"award-info":[{"award-number":["468853597"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202208310049"],"award-info":[{"award-number":["202208310049"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Access funding enabled and organized by Projekt DEAL"},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40263-025-01218-z","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T02:59:49Z","timestamp":1755658789000},"page":"937-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose\u2013Response Meta-analysis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-3879","authenticated-orcid":false,"given":"Xiao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-3538","authenticated-orcid":false,"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-7439","authenticated-orcid":false,"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9045-3801","authenticated-orcid":false,"given":"Mengchang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9532","authenticated-orcid":false,"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"11","key":"1218_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/s2215-0366(23)00262-6","volume":"10","author":"T Pillinger","year":"2023","unstructured":"Pillinger T, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023;10(11):860\u201376. https:\/\/doi.org\/10.1016\/s2215-0366(23)00262-6.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"1218_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13422","volume":"36","author":"K Liu","year":"2024","unstructured":"Liu K, et al. The research trend of hyperprolactinemia from 2011 to 2023 was analyzed by bibliometrics. J Neuroendocrinol. 2024;36(9): e13422. https:\/\/doi.org\/10.1111\/jne.13422.","journal-title":"J Neuroendocrinol"},{"issue":"20","key":"1218_CR3","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314. https:\/\/doi.org\/10.2165\/00003495-200464200-00003.","journal-title":"Drugs"},{"issue":"1","key":"1218_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/schbul\/sbac152","volume":"49","author":"M Solmi","year":"2023","unstructured":"Solmi M, et al. Antipsychotic use and risk of low-energy fractures in people with schizophrenia: a nationwide nested case-control study in Finland. Schizophr Bull. 2023;49(1):78\u201389. https:\/\/doi.org\/10.1093\/schbul\/sbac152.","journal-title":"Schizophr Bull"},{"issue":"10","key":"1218_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, et al. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883\u201391. https:\/\/doi.org\/10.1016\/s2215-0366(21)00241-8.","journal-title":"Lancet Psychiatry"},{"issue":"2 Suppl","key":"1218_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0269881107088439","volume":"22","author":"V O\u2019Keane","year":"2008","unstructured":"O\u2019Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70\u20135. https:\/\/doi.org\/10.1177\/0269881107088439.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1218_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/YIC.0b013e328341e434","volume":"26","author":"A Serretti","year":"2011","unstructured":"Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130\u201340. https:\/\/doi.org\/10.1097\/YIC.0b013e328341e434.","journal-title":"Int Clin Psychopharmacol"},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0306-4530(02)00127-0","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55\u201368. https:\/\/doi.org\/10.1016\/s0306-4530(02)00127-0.","journal-title":"Psychoneuroendocrinology"},{"issue":"11","key":"1218_CR9","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","volume":"65","author":"J Montgomery","year":"2004","unstructured":"Montgomery J, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491\u20138. https:\/\/doi.org\/10.4088\/JCP.v65n1108.","journal-title":"J Clin Psychiatry"},{"key":"1218_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/175360","volume":"2014","author":"RP Rajkumar","year":"2014","unstructured":"Rajkumar RP. Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr Res Treat. 2014;2014: 175360. https:\/\/doi.org\/10.1155\/2014\/175360.","journal-title":"Schizophr Res Treat"},{"issue":"10202","key":"1218_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(19)31135-3.","journal-title":"Lancet"},{"issue":"2","key":"1218_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208\u201324. https:\/\/doi.org\/10.1002\/wps.20632.","journal-title":"World Psychiatry"},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","volume":"237","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr Res. 2021;237:20\u20135. https:\/\/doi.org\/10.1016\/j.schres.2021.08.013.","journal-title":"Schizophr Res"},{"key":"1218_CR14","unstructured":"Leucht S, et al. Dose-response meta-analysis of the efficacy and side-effects of antipsychotic drugs in schizophrenia. PROSPERO, 2020:CRD42020181467. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020181467"},{"issue":"8","key":"1218_CR15","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","volume":"28","author":"S Siafis","year":"2023","unstructured":"Siafis S, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023;28(8):3267\u201377. https:\/\/doi.org\/10.1038\/s41380-023-02203-y.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1218_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","volume":"48","author":"H Wu","year":"2022","unstructured":"Wu H, et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull. 2022;48(3):643\u201354. https:\/\/doi.org\/10.1093\/schbul\/sbac001.","journal-title":"Schizophr Bull"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.euroneuro.2023.03.015","volume":"72","author":"H Wu","year":"2023","unstructured":"Wu H, et al. Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis. Eur Neuropsychopharmacol. 2023;72:40\u20139. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.015.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1218_CR18","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Chichester: Wiley; 2011."},{"issue":"5","key":"1218_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1177\/0962280218773122","volume":"28","author":"A Crippa","year":"2019","unstructured":"Crippa A, et al. One-stage dose\u2013response meta-analysis for aggregated data. Stat Methods Med Res. 2019;28(5):1579\u201396. https:\/\/doi.org\/10.1177\/0962280218773122.","journal-title":"Stat Methods Med Res"},{"key":"1218_CR20","doi-asserted-by":"publisher","unstructured":"Crippa A, Orsini N. Multivariate dose-response meta-analysis: the dosresmeta R package. J Stat Softw. 2016;72(1):1\u201315. https:\/\/doi.org\/10.18637\/jss.v072.c01","DOI":"10.18637\/jss.v072.c01"},{"issue":"2\u20133","key":"1218_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"F Misawa","year":"2016","unstructured":"Misawa F, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2\u20133):220\u201330. https:\/\/doi.org\/10.1016\/j.schres.2016.07.018.","journal-title":"Schizophr Res"},{"issue":"10327","key":"1218_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824\u201336.","journal-title":"Lancet"},{"issue":"4","key":"1218_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4088\/JCP.14m09741","volume":"76","author":"HY Meltzer","year":"2015","unstructured":"Meltzer HY, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76:1085. https:\/\/doi.org\/10.4088\/JCP.14m09741.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1218_CR25","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.4088\/JCP.14m09168","volume":"75","author":"JM Kane","year":"2014","unstructured":"Kane JM, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254\u201360. https:\/\/doi.org\/10.4088\/JCP.14m09168.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1218_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/s1461145704004262","volume":"7","author":"P Oosthuizen","year":"2004","unstructured":"Oosthuizen P, et al. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol. 2004;7(2):125\u201331. https:\/\/doi.org\/10.1017\/s1461145704004262.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"1218_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125\u201332. https:\/\/doi.org\/10.1176\/appi.ajp.160.6.1125.","journal-title":"Am J Psychiatry"},{"key":"1218_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-020-00127-y","author":"CU Correll","year":"2020","unstructured":"Correll CU, et al. Efficacy and safety of once-monthly Risperidone ISM\u00ae in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020. https:\/\/doi.org\/10.1038\/s41537-020-00127-y.","journal-title":"NPJ Schizophr"},{"issue":"2","key":"1218_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/jcp.0000000000000479","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130\u201340. https:\/\/doi.org\/10.1097\/jcp.0000000000000479.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1218_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1017\/s0033291719003957","volume":"51","author":"S Siafis","year":"2021","unstructured":"Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from \u2018major tranquilizers\u2019 to neuroscience-based-nomenclature. Psychol Med. 2021;51(3):522\u20134. https:\/\/doi.org\/10.1017\/s0033291719003957.","journal-title":"Psychol Med"},{"issue":"22","key":"1218_CR31","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","volume":"234","author":"J Grigg","year":"2017","unstructured":"Grigg J, et al. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology. 2017;234(22):3279\u201397. https:\/\/doi.org\/10.1007\/s00213-017-4730-6.","journal-title":"Psychopharmacology"},{"key":"1218_CR32","unstructured":"Kolnikaj TS, et al. Pharmacological causes of hyperprolactinemia. In: Endotext, Feingold KR, et al., editors. MDText.com, Inc. Copyright \u00a9 2000\u20132024. South Dartmouth: MDText.com, Inc.; 2000."},{"issue":"7","key":"1218_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.pnpbp.2010.07.003","volume":"34","author":"Y Suzuki","year":"2010","unstructured":"Suzuki Y, et al. Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1266\u20138. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.07.003.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1218_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060907","author":"M Romanescu","year":"2022","unstructured":"Romanescu M, et al. Sex-related differences in pharmacological response to CNS drugs: a narrative review. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12060907.","journal-title":"J Pers Med"},{"issue":"4","key":"1218_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1365-2125.2001.01352.x","volume":"51","author":"KI Melkersson","year":"2001","unstructured":"Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001;51(4):317\u201324. https:\/\/doi.org\/10.1046\/j.1365-2125.2001.01352.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1218_CR36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","volume":"172","author":"CU Correll","year":"2015","unstructured":"Correll CU, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870\u201380. https:\/\/doi.org\/10.1176\/appi.ajp.2015.14101275.","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"1218_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","volume":"164","author":"JM Kane","year":"2015","unstructured":"Kane JM, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1\u20133):127\u201335. https:\/\/doi.org\/10.1016\/j.schres.2015.01.038.","journal-title":"Schizophr Res"},{"issue":"1","key":"1218_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359. https:\/\/doi.org\/10.1007\/s40263-020-00779-5.","journal-title":"CNS Drugs"},{"issue":"3","key":"1218_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","volume":"79","author":"H Taipale","year":"2022","unstructured":"Taipale H, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiatr. 2022;79(3):210\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.3990.","journal-title":"JAMA Psychiatr"},{"issue":"9","key":"1218_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaac.2023.03.007","volume":"62","author":"MT Koch","year":"2023","unstructured":"Koch MT, et al. Antipsychotic-related prolactin levels and sexual dysfunction in mentally ill youth: a 3-month cohort study. J Am Acad Child Adolesc Psychiatry. 2023;62(9):1021\u201350. https:\/\/doi.org\/10.1016\/j.jaac.2023.03.007.","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"updated-by":[{"DOI":"10.1007\/s40263-025-01243-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01218-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:10:33Z","timestamp":1762881033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01218-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01218-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected. Figure 1 has been replaced.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-025-01243-y","URL":"https:\/\/doi.org\/10.1007\/s40263-025-01243-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In the last 3\u00a0years, C.U. Correll has been a consultant and\/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals; he provided expert testimony for Janssen, Lundbeck, and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, and Rovi; he has received grant support from Boehringer-Ingelheim, Janssen, and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. In the last 3\u00a0years, S.L. has received honoraria for advising\/consulting and\/or for lectures and\/or for educational material from Angelini, Boehringer Ingelheim, Eisai, Ekademia, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Mitsubishi, Otsuka, NovoNordisk, Recordati, Rovi, and Teva. H.W. is currently an employee of Elsevier in the role of senior editor for The Lancet Public Health. Her contribution happened before she was employed by Elsevier and she had no role in the editorial evaluation, peer-review process or decision to accept the article.\u00a0All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The full dataset is available from the study authors upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This meta-analysis was conducted within the framework of a larger project funded by the Deutsche Forschungsgemeinschaft (German Research Foundation, grant no. 468853597). Xiao Lin receives support from The China Scholarship Council PhD program (file no. 202208310049). Publication fee is covered by institutional funding by Technical University of Munich.\u00a0None of the funding institutions contributed to the study design, data analysis, manuscript writing, or the decision to submit the paper for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Code is available from the corresponding author upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"S.L., S.S., J.S.T., and X.L. designed the review; S.L., H.W., S.S., X.L., J.T., and M.Q. were responsible for the literature search, article screening, and data extraction; X.L. conducted the statistical analysis under the guidance of J.S.T. and S.S; and X.L., J.S.T., and S.L. drafted the article. All authors critically revised the article for important intellectual content and approved the final version submitted for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}